Premium
Mutations in Keap1 are a potential prognostic factor in resected non‐small cell lung cancer
Author(s) -
Takahashi Tsuyoshi,
Sonobe Makoto,
Menju Toshi,
Nakayama Ei,
Mino Nobuya,
Iwakiri Shotaro,
Nagai Shinjiro,
Sato Kiyoshi,
Miyahara Ryo,
Okubo Kenichi,
Hirata Toshiki,
Date Hiroshi,
Wada Hiromi
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21520
Subject(s) - medicine , pathological , lung cancer , stage (stratigraphy) , oncology , cancer , survival rate , mutation , keap1 , gene mutation , disease , gastroenterology , gene , pathology , cancer research , biology , genetics , paleontology , transcription factor
Background Mutations in Kelch‐like ECH‐associated protein 1 (Keap1) have been reported to protect tumor cells from chemotherapeutic agents. However, their prognostic significance in nonsmall cell lung cancer (NSCLC) is still unclear. In this study, we examined the effect of Keap1 gene mutations on survival and disease‐free interval using resected primary NSCLC tissue. Methods We retrospectively analyzed the tumors from 79 patients with completely resected pathological Stage I–II NSCLC for the presence of Keap1 gene mutations and examined the prognosis of the patients. Results Keap1 gene mutations were detected in four patients (5.1%). The postoperative 5‐year survival rate for patients with Keap1 mutations was significantly lower than those without a mutation (25% vs. 76%, P = 0.038). The postoperative 5‐year disease‐free survival rate for patients with a mutant Keap1 tumor was slightly lower than for patients with Keap1 wild‐type tumors (25% vs. 66%, P = 0.057). Conclusions Keap1 gene mutations are likely to be associated with a worse prognosis and lower postoperative disease‐free survival rates in pathological Stage I–II NSCLC. J. Surg. Oncol. 2010; 101:500–506. © 2010 Wiley‐Liss, Inc.